Abstract Library

#3895 NGS in G1-G2 pancreatic NETs – Data collection at University Hospital of Verona

Introduction: Pancreatic neuroendocrine tumors (pNETs) are known to have few druggable gene alterations. One possible area of interest concerns the possibility of giving better biological connotations to the >10% subgroup.

Conference:

Presenting Author: Borghesani M

Authors: Borghesani M, Mafficini A, Luchini C, Scarpa A, Milella M,

Keywords: NGS, neuroendocrine, pancreatic,

#3892 Precision medicine in pancreatic MiNEN and other rare pancreatic histologies – A case series from Verona University Hospital

Introduction: Rare tumors of the pancreas represent orphan neoplasms. Better knowledge of their biology will allow more effective treatments to be offered to affected patients.

Conference:

Presenting Author: Trevisani E

Authors: Trevisani E, Mafficini A, Benini L, Borghesani M, Rossi A,

Keywords: Precision medicine, rare pancreas, NGS, gene mutation, MiNEN,

#3891 Exceptional response to Everolimus in a pancreatic NET G3 (pNET) – How NGS can help in treatment choice

Introduction: Exceptional Responders are defined as patients who achieve complete (CR) or partial response (PR) for at least 6 months to a treatment with population PR or CR rate less than 10%, or patients with CR or PR lasting more than three times the median duration of response.

Conference:

Presenting Author: Torresan I

Authors: Torresan I, Mafficini A, Benini L, Borghesani M, Moscarda V,

Keywords: pNET, NGS, G3, everolimus, TSC2,

#3757 Subtype-specific landscape of splicing-associated neoantigens and mutations in pancreatic neuroendocrine tumors

Introduction: In pancreatic neuroendocrine tumors (PanNETs), there has recently been advancement in understanding the heterogeneity (metastases-like primary; MLP-1/2, intermediate, and insulinoma subtypes) and immunological landscapes. Immunotherapies provide modest therapeutic benefits to patients, which may be linked to low mutational neoantigen loads in PanNETs.

Conference:

Presenting Author: Sadanandam A

Authors: Sadanandam A, Lawlor R, Larkeryd A, Mahalingam A, Mafficini A,

Keywords: Pancreatic neuroendocrine tumor, isoform switching, subtype, mutation, neoantigens, splice variant, spliceosomal mutation, immunotherapy, immunosuppression,

#3183 Clinical stratification of pancreatic neuroendocrine tumors by systematically integrating multimodal and clinical data

Introduction: Non-functional pancreatic neuroendocrine tumors (PanNETs) are heterogeneous with at least two transcriptome subtypes with differential biology, immune mechanisms and prognosis. However, it is challenging to understand how multimodal data interact with clinical variables and contribute to the disease heterogeneity and phenotypes.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Lawlor R, Mafficini A, Luchini C, Nyamundanda G,

Keywords: pancreatic neuroendocrine tumor, multimodal data integration, multiomics, clinical data integration, machine learning, artificial intelligence, subtypes, pancreatic cancer, phenotypes, PhenMap, mutations, gene expression, microRNA,